Immatics Announces Second Quarter 2023 Financial Results and Business Update
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program…
Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program…
Das „DeepTech“-Unternehmen AB-CT – Advanced Breast-CT stellt sich mit einem erweiterten Führungsteam neu auf. Den Bereic…
Das ASCO® Annual Meeting hat 2023 wieder in Präsenz in Chicago stattgefunden. Auch ASCO DirectTM war wieder mit einem Te…
. Rapid.Tech 3D 9 – 11 May 2023, Messe Erfurt, Germany The exhibition and award ceremony of the eighth edition of the…
Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA2…
The 3D Pioneers Challenge (3DPC), the platform for additive manufacturing and advanced technologies, presents the pionee…
Focus on environmental steel production, improving quality requirements and increasing productivity Modernization r…
Körperlich aktive Frauen haben nach einer Brustkrebsdiagnose ein geringeres Sterblichkeitsrisiko - das konnten frühere S…
faCellitate GmbH has appointed Dr. Christoph Petry, as Managing Director and CEO. Dr. Petry spun-out Sividon Diagnostics…
Interim clinical update on ACTengine® IMA203 TCR-T monotherapy targeting PRAME demonstrated high confirmed objective res…